Original Article

Indian Journal of Otolaryngology and Head & Neck Surgery

, Volume 66, Issue 4, pp 386-393

First online:

Allergic Rhinitis in Children: A Randomized Clinical Trial Targeted at Symptoms

  • Nicola MansiAffiliated withS.C. di Otorinolaringoiatria della A.O.R.N. Santobono Pausilipon di Napoli
  • , Gabriele D’AgostinoAffiliated withS.C. di Otorinolaringoiatria della A.O.R.N. Santobono Pausilipon di Napoli
  • , Antonella Silvia ScirèAffiliated withZeta Research Srl
  • , Giada MorpurgoAffiliated withZeta Research Srl
  • , Dario GregoriAffiliated withUnit of Biostatistics, Epidemiology and Public Health, Department of Cardiac, Thoracic and Vascular Sciences, University of Padova Email author 
  • , Achal GulatiAffiliated withE.N.T. Department, Maulana Azad Medical College and LN
  • , Valerio DamianiAffiliated withENT Department San Giovanni Addolorata Hospital

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Allergic rhinitis (AR) underlies many symptoms and complications which severely affect children’s quality of life. This two-arm study aimed at evaluate the efficacy and safety of the medical device Narivent® versus topical corticosteroids in the symptomatic management of allergic rhinitis in paediatric patients. A randomized study was conducted. Forty subjects with a diagnosis of allergic rhinitis were randomized to receive one puff of Narivent® into each nostril twice daily for 30 days (n = 20) or to receive one puff of topical intranasal corticosteroid into each nostril twice daily for 30 days (n = 20). In both treatment arms, severity of major symptoms related to AR, including nasal congestion, rhinorrhoea, sneezing and nasal itching, was assessed subjectively on a 0–100 mm visual analogue scale. Nasal congestion, rhinorrhoea and sneezing improved significantly after 30 days of treatment with Narivent®. Similarly, in topical steroids group severity of all subjective symptoms decreased significantly. Narivent® appears to be efficacious in treating nasal congestion and other major symptoms in children with AR over a 30-day period, showing comparable results to intranasal corticosteroids therapy but with a better safety profile.


Intranasal corticosteroids Osmotically-acting medical device Anti-oedematous Anti-inflammatory Allergic rhinitis Children